
ReNerve Limited Asian Market Update – NervAlign® Nerve Cuff
Marketing Approval in Thailand & Initial Sales in Hong Kong Highlights: • ReNerve has received marketing approval for its NervAlign®… Read more
Marketing Approval in Thailand & Initial Sales in Hong Kong Highlights: • ReNerve has received marketing approval for its NervAlign®… Read more
ReNerve Limited (ASX:RNV) (“ReNerve” or “the Company”) is pleased to announce that it has received an additional tax refund of… Read more
Highlights: • Strong Sales Growth: US sales increased by approximately 100% in 2024 compared to 2023. Revenue for 1H FY25… Read more
Highlights: • ReNerve has entered a partnership with Imbiomex to progress the NervAlign® Nerve Cuff through regulatory approval and thereafter… Read more
Development of Novel Nerve Repair & Regeneration Products ReNerve is focused on developing a portfolio of products for the nerve… Read more
Highlights: • ReNerve Limited (“ReNerve” or “the Company”) commenced trading on the ASX on 26 November 2024 following a heavily… Read more
Highlights: ● ReNerve Limited has partnered with Union MediScience B.S.C in an exclusive distribution agreement for the sales and marketing… Read more
Highlights: ● ReNerve Limited has partnered with Accession Medical Supplies Co in an exclusive distribution agreement for sales and marketing… Read more
ReNerve is pleased to provide its latest Investor Presentation.